A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated LDL-C Levels.